Obese postmenopausal women with ER+ breast cancer treated with AIs in the adjuvant setting also experience inferior breast cancer outcomes, possibly due to inadequate suppression of aromatase, which is produced in adipose tissue31–33 and this has been observed among premenopausal women as well33. Here, CYP19A1 is linked to breast carcinoma.